Genetic, Surgical and Oncological Approach to Breast Cancer, with BRCA1, BRCA2, CDH1, PALB2, PTEN and TP53 Variants

Objective:The aim of this study was to determine the frequency of germline variants in BRCA1, BRCA2, CDH1, PALB2, PTEN and TP53 in patients admitted to a medical genetics clinic with breast cancer and to assess these identified variants according to published genetic, surgical and oncological perspe...

Full description

Bibliographic Details
Main Authors: Aslı Subaşıoğlu, Zeynep Gülsüm Güç, Emine Özlem Gür, Mustafa Agah Tekindal, Murat Kemal Atahan
Format: Article
Language:English
Published: Galenos Publishing House 2023-01-01
Series:European Journal of Breast Health
Subjects:
Online Access: http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/genetic-surgical-and-oncological-approach-to-breas/57737
_version_ 1797916870002606080
author Aslı Subaşıoğlu
Zeynep Gülsüm Güç
Emine Özlem Gür
Mustafa Agah Tekindal
Murat Kemal Atahan
author_facet Aslı Subaşıoğlu
Zeynep Gülsüm Güç
Emine Özlem Gür
Mustafa Agah Tekindal
Murat Kemal Atahan
author_sort Aslı Subaşıoğlu
collection DOAJ
description Objective:The aim of this study was to determine the frequency of germline variants in BRCA1, BRCA2, CDH1, PALB2, PTEN and TP53 in patients admitted to a medical genetics clinic with breast cancer and to assess these identified variants according to published genetic, surgical and oncological perspectives.Materials and Methods:Medical history, and cancer diagnosis information for 195 independent probands with operated breast cancer were collected from requisition forms and medical records. The exonic regions and exon-intron junctions in BRCA1, BRCA2, CDH1, PALB2, PTEN and TP53 genes were sequenced. Analysis of fastq files was performed on the Qiagen Clinical Insight-Analyse Universal with panel-specific pipeline and vcf files were interpreted clinically using Qiagen Clinical Insight-Interpret.Results:Gene variants (pathogenic, likely pathogenic and variants of unknown significance) were detected in 53 (27.2%). Detailed information about the patients (age of diagnosis, family history, gender), cancer stage, tumour characteristics (ER, PR, human epidermal growth factor receptor 2 status) and all information related to the detected variants (gene, location, nucleotide and amino acid change, exon number, impact, mutation classification, dbSNP number and HGMD variant class) were assessed. In total, 58 mutations were identified including 14 novel, previously unreported variants.Conclusion:Molecular characterization and identification of mutations have important implications for predictive, preventive, and personalized medicine, including genetic counseling and development of specific treatment protocols. We emphasize variants of unknown significance (VUS) as the clinical significance of VUS changes over time and variant classification is important for clinical molecular genetic testing and clinical guidance. This study may provide new insights into risk assessment for variants in CDH1, PALB2, PTEN and TP53, in addition to BRCA1 and BRCA2, which may prove useful for clinical management of breast cancer patients. Further studies are needed to identify the common gene variants in the Turkish population and evaluate the pathogenity of VUS.
first_indexed 2024-04-10T13:05:16Z
format Article
id doaj.art-c43d342e939c4909b796a24d13cc4dc8
institution Directory Open Access Journal
issn 2587-0831
language English
last_indexed 2024-04-10T13:05:16Z
publishDate 2023-01-01
publisher Galenos Publishing House
record_format Article
series European Journal of Breast Health
spelling doaj.art-c43d342e939c4909b796a24d13cc4dc82023-02-15T16:13:00ZengGalenos Publishing HouseEuropean Journal of Breast Health2587-08312023-01-01191556910.4274/ejbh.galenos.2022.2022-7-213049054Genetic, Surgical and Oncological Approach to Breast Cancer, with BRCA1, BRCA2, CDH1, PALB2, PTEN and TP53 VariantsAslı Subaşıoğlu0Zeynep Gülsüm Güç1Emine Özlem Gür2Mustafa Agah Tekindal3Murat Kemal Atahan4 Department of Medical Genetics, İzmir Katip Çelebi University Faculty of Medicine, İzmir, Turkey Department of Medical Oncology, İzmir Katip Çelebi University Faculty of Medicine, İzmir, Turkey Department of General Surgery, İzmir Katip Çelebi University Faculty of Medicine, İzmir, Turkey Department of Biostatistics, İzmir Katip Çelebi University Faculty of Medicine, İzmir, Turkey Department of General Surgery, İzmir Katip Çelebi University Faculty of Medicine, İzmir, Turkey Objective:The aim of this study was to determine the frequency of germline variants in BRCA1, BRCA2, CDH1, PALB2, PTEN and TP53 in patients admitted to a medical genetics clinic with breast cancer and to assess these identified variants according to published genetic, surgical and oncological perspectives.Materials and Methods:Medical history, and cancer diagnosis information for 195 independent probands with operated breast cancer were collected from requisition forms and medical records. The exonic regions and exon-intron junctions in BRCA1, BRCA2, CDH1, PALB2, PTEN and TP53 genes were sequenced. Analysis of fastq files was performed on the Qiagen Clinical Insight-Analyse Universal with panel-specific pipeline and vcf files were interpreted clinically using Qiagen Clinical Insight-Interpret.Results:Gene variants (pathogenic, likely pathogenic and variants of unknown significance) were detected in 53 (27.2%). Detailed information about the patients (age of diagnosis, family history, gender), cancer stage, tumour characteristics (ER, PR, human epidermal growth factor receptor 2 status) and all information related to the detected variants (gene, location, nucleotide and amino acid change, exon number, impact, mutation classification, dbSNP number and HGMD variant class) were assessed. In total, 58 mutations were identified including 14 novel, previously unreported variants.Conclusion:Molecular characterization and identification of mutations have important implications for predictive, preventive, and personalized medicine, including genetic counseling and development of specific treatment protocols. We emphasize variants of unknown significance (VUS) as the clinical significance of VUS changes over time and variant classification is important for clinical molecular genetic testing and clinical guidance. This study may provide new insights into risk assessment for variants in CDH1, PALB2, PTEN and TP53, in addition to BRCA1 and BRCA2, which may prove useful for clinical management of breast cancer patients. Further studies are needed to identify the common gene variants in the Turkish population and evaluate the pathogenity of VUS. http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/genetic-surgical-and-oncological-approach-to-breas/57737 brca1/2breast cancercdh1/palb2genetic testingtp53/pten
spellingShingle Aslı Subaşıoğlu
Zeynep Gülsüm Güç
Emine Özlem Gür
Mustafa Agah Tekindal
Murat Kemal Atahan
Genetic, Surgical and Oncological Approach to Breast Cancer, with BRCA1, BRCA2, CDH1, PALB2, PTEN and TP53 Variants
European Journal of Breast Health
brca1/2
breast cancer
cdh1/palb2
genetic testing
tp53/pten
title Genetic, Surgical and Oncological Approach to Breast Cancer, with BRCA1, BRCA2, CDH1, PALB2, PTEN and TP53 Variants
title_full Genetic, Surgical and Oncological Approach to Breast Cancer, with BRCA1, BRCA2, CDH1, PALB2, PTEN and TP53 Variants
title_fullStr Genetic, Surgical and Oncological Approach to Breast Cancer, with BRCA1, BRCA2, CDH1, PALB2, PTEN and TP53 Variants
title_full_unstemmed Genetic, Surgical and Oncological Approach to Breast Cancer, with BRCA1, BRCA2, CDH1, PALB2, PTEN and TP53 Variants
title_short Genetic, Surgical and Oncological Approach to Breast Cancer, with BRCA1, BRCA2, CDH1, PALB2, PTEN and TP53 Variants
title_sort genetic surgical and oncological approach to breast cancer with brca1 brca2 cdh1 palb2 pten and tp53 variants
topic brca1/2
breast cancer
cdh1/palb2
genetic testing
tp53/pten
url http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/genetic-surgical-and-oncological-approach-to-breas/57737
work_keys_str_mv AT aslısubasıoglu geneticsurgicalandoncologicalapproachtobreastcancerwithbrca1brca2cdh1palb2ptenandtp53variants
AT zeynepgulsumguc geneticsurgicalandoncologicalapproachtobreastcancerwithbrca1brca2cdh1palb2ptenandtp53variants
AT emineozlemgur geneticsurgicalandoncologicalapproachtobreastcancerwithbrca1brca2cdh1palb2ptenandtp53variants
AT mustafaagahtekindal geneticsurgicalandoncologicalapproachtobreastcancerwithbrca1brca2cdh1palb2ptenandtp53variants
AT muratkemalatahan geneticsurgicalandoncologicalapproachtobreastcancerwithbrca1brca2cdh1palb2ptenandtp53variants